Overview

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-09-27
Target enrollment:
Participant gender:
Summary
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Phase:
PHASE3
Details
Lead Sponsor:
Ocular Therapeutix, Inc.
Collaborators:
Duke University
Fortrea
Treatments:
aflibercept
Axitinib